Orchestra BioMed Hldgs Analyst Ratings
Orchestra BioMed Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/24/2023 | 45.63% | Piper Sandler | → $15 | Initiates Coverage On | → Overweight |
| 02/07/2023 | 94.17% | Chardan Capital | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 02/24/2023 | 45.63% | 派珀·桑德勒 | → 15 美元 | 开启覆盖范围 | → 超重 |
| 02/07/2023 | 94.17% | 查丹资本 | → 20 美元 | 开启覆盖范围 | → 购买 |
What is the target price for Orchestra BioMed Hldgs (OBIO)?
Orchestra BioMed Hldgs（OBIO）的目标价格是多少？
The latest price target for Orchestra BioMed Hldgs (NASDAQ: OBIO) was reported by Piper Sandler on February 24, 2023. The analyst firm set a price target for $15.00 expecting OBIO to rise to within 12 months (a possible 45.63% upside). 2 analyst firms have reported ratings in the last year.
派珀·桑德勒于2023年2月24日公布了Orchestra BioMed Hldgs（纳斯达克股票代码：OBIO）的最新目标股价。这家分析公司将目标价设定为15.00美元，预计OBIO将在12个月内升至12个月（可能上涨45.63％）。去年，有两家分析公司公布了评级。
What is the most recent analyst rating for Orchestra BioMed Hldgs (OBIO)?
Orchestra BioMed Hldgs（OBIO）的最新分析师评级是多少？
The latest analyst rating for Orchestra BioMed Hldgs (NASDAQ: OBIO) was provided by Piper Sandler, and Orchestra BioMed Hldgs initiated their overweight rating.
Orchestra BioMed Hldgs（纳斯达克股票代码：OBIO）的最新分析师评级由派珀·桑德勒提供，Orchestra BioMed Hldgs开始了增持评级。
When is the next analyst rating going to be posted or updated for Orchestra BioMed Hldgs (OBIO)?
Orchestra BioMed Hldgs（OBIO）的下一个分析师评级将在何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchestra BioMed Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchestra BioMed Hldgs was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括浏览公开财务报表，与Orchestra BioMed Hldgs的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月这样做一次，因此每家公司每年应该获得4次评级。Orchestra BioMed Hldgs的最新评级是在2023年2月24日提交的，因此你应该预计下一个评级将在2024年2月24日左右公布。
Is the Analyst Rating Orchestra BioMed Hldgs (OBIO) correct?
分析师对管弦乐团 BioMed Hldgs（OBIO）的评级正确吗？
While ratings are subjective and will change, the latest Orchestra BioMed Hldgs (OBIO) rating was a initiated with a price target of $0.00 to $15.00. The current price Orchestra BioMed Hldgs (OBIO) is trading at is $10.30, which is within the analyst's predicted range.
虽然评级是主观的，而且会发生变化，但最新的Orchestra BioMed Hldgs（OBIO）评级最初是以0.00美元至15.00美元的目标股价为0.00美元至15.00美元。Orchestra BioMed Hldgs（OBIO）目前的交易价格为10.30美元，在分析师的预测区间内。